EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

S H L Telemedicine Ltd (SHLTN) fair value: what the stock is really worth

As of Oct 14, 2026: fair value of S H L Telemedicine Ltd CHF 1.11, price CHF 1.07, upside +3.3%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · CH · Home Israel · ISIN IL0010855885

SH S H L Telemedicine Ltd logo Thin data Oct 2, 2026

S H L Telemedicine Ltd

SHLTN · SW

Low PriorityFair Value upside is limited and quality is weak.

The stock costs about what our calculation considers fair.

Low debt
Fair value CHF 1.11 · Fairly valued (+3.3%)
Expensive Growth (revenue 5y +8.9 %/yr in USD)
Mixed vs. peers (4/10)
Quality 37/100
Loss-making · -24.1% net margin (TTM)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch S H L Telemedicine Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 11.00 CHF 0.4565 Fair Value CHF 1.11 Mar 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range CHF 0.4565 – CHF 11.00 · fair‑value band CHF 0.8840 – CHF 1.33 · the CHF 1.07 price screens below the CHF 1.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 2, 2026.

Follow S H L Telemedicine in your weekly email

Every Wednesday you see whether S H L Telemedicine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SHL Telemedicine Ltd., together with its subsidiaries, provides telemedicine services in Israel, Europe, and internationally.

Show moreShow less

The company offers SmartHeart platform, a 12-lead electrocardiogram (ECG) that enables a full, hospital-quality ECG to be performed by a lay-person without the assistance of a healthcare professional.

It also provides preventative healthcare, including annual medical check-ups that include comprehensive laboratory tests, stress ECG tests, eye exams, and others; witness services for medical experts and medical committees; and occupational healthcare, including occupational safety and health regulated medical exams, exposure to hazardous materials, and occupational disability claims, as well as assisting organizations in promoting early detection of diseases and medical conditions within the workforce by offering periodical check-ups and specialized examinations.

In addition, the company offers medical examinations, including at home, for the underwriting of insurance policies for health, disability, life, or nursing home policyholders; medical and psychological evaluations, including for truck drivers, public transportation drivers, and drivers of hazardous cargos; remote monitoring of chronic patients; telehealth hot-line services; and doctors' virtual visits.

It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart 12 lead ECG. SHL Telemedicine Ltd. was incorporated in 1986 and is headquartered in Tel Aviv-Yafo, Israel.

Stock analysis

S H L Telemedicine Ltd (SHLTN) currently trades at CHF 1.07, while our model-based Fair Value estimate is CHF 1.11, so the stock looks roughly fairly valued today (gap 3.2%).

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: CHF 0.8840 (bear) to CHF 1.33 (bull), the price of CHF 1.07 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

S H L Telemedicine Ltd reported revenue of $61.5M in FY2025 versus $49.6M in FY2021, a compound +5.5%/yr. Reported net income was −$16.1M in FY2025.

Key figures

Market cap CHF 39.7M · P/S ratio 0.64 · EPS (TTM) CHF −0.5100 · Net margin −26.2% · Return on equity −36.9% · Return on assets (EBIT) −10.4% · Operating margin −8.9% · Revenue (TTM) $62.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 87% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 3%, SHLTN screens richer than that median.

Fair Value models

Bear CHF 0.8840 Fair Value CHF 1.11 Bull CHF 1.33
Price CHF 1.07 · Upside +3.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA CHF 1.19 CHF 1.44 CHF 1.70 67
NCAV (Graham) CHF 0.4900 CHF 0.6600 CHF 0.9800 54
All 2 models by family
Multiples
EV/EBITDA CHF 1.19 CHF 1.44 CHF 1.70 67
Asset-Based
NCAV (Graham) CHF 0.4900 CHF 0.6600 CHF 0.9800 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 61
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 64
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 81
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Start year 2020 (pandemic). Over 10 years: +5.9% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.0% (2020) → −7.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SHLTN, get fair value alerts →

Compare S H L Telemedicine Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 116 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside +3.3% · Above median
Profitability
Return on assets −19.1% · Bottom 25%
Net margin (12 months) −24.1% · Bottom 25%
Operating margin (12 months) −8.9% · Below median
Growth and dividend
Revenue growth 12.2% · Above median
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 1.09× · Cheaper than median
P/S (12 months) 0.77× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)38 · sector 0
FUTURE (revenue growth)61 · sector 41
PAST (return on equity)0 · sector 10
HEALTH (low debt)92 · sector 98
DIVIDEND (yield)0 · sector 43

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $295.85 $325.44 +10% vs SHLTN
HealthEquity, Inc HQY $88.44 $97.28 +10% vs SHLTN
Doximity, Inc DOCS $30.50 $33.55 +10% vs SHLTN
Waystar Holding WAY $26.68 $29.10 +9% vs SHLTN
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6% vs SHLTN
Pro Medicus Limited PME A$168.37 A$84.62 −50% vs SHLTN
Hinge Health, Inc HNGE $102.90 $51.25 −50% vs SHLTN
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54% vs SHLTN
Privia Health Group PRVA $19.62 $5.02 −74% vs SHLTN
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81% vs SHLTN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

S H L Telemedicine Ltd · Fair Value
CHF 1.11 +3%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "S H L Telemedicine Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SHLTN

Frequently asked questions

Is S H L Telemedicine Ltd (SHLTN) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of CHF 1.11 versus a price of CHF 1.07, about +3% upside (fairly valued).
What is the fair value of SHLTN?
Our model-based fair value for S H L Telemedicine Ltd is CHF 1.11 (as of Oct 2, 2026), built from audited fundamentals. The current price: CHF 1.07.
What is the quality score of SHLTN?
S H L Telemedicine Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for S H L Telemedicine Ltd (SHLTN)?
Our model-based price target is the fair value of CHF 1.11 (as of Oct 2, 2026) from 2 valuation models. Cautious scenario CHF 0.8840, optimistic scenario CHF 1.33. It is a calculation from audited fundamentals, not an analyst target.
What is the S H L Telemedicine Ltd stock forecast for 2026?
Our models put fair value at CHF 1.11, about +3% upside versus a price of CHF 1.07 (fairly valued). Cautious scenario CHF 0.8840, optimistic scenario CHF 1.33. The calculation is refreshed regularly with new filings.
What is the revenue of S H L Telemedicine Ltd (SHLTN)?
S H L Telemedicine Ltd reported trailing-twelve-month revenue of about $62.1M (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of S H L Telemedicine Ltd (SHLTN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For S H L Telemedicine Ltd it is CHF 1.11 per share (as of Oct 2, 2026), against a price of CHF 1.07. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is S H L Telemedicine Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, SHLTN trades below its calculated fair value: price CHF 1.07, fair value CHF 1.11, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SHLTN?
No. The price is what the market pays today (CHF 1.07); the fair value is what the company's own numbers justify (CHF 1.11). For S H L Telemedicine Ltd the two are CHF 0.0350 per share apart. That gap is exactly why we show both numbers side by side.
How much is S H L Telemedicine Ltd worth?
The market values S H L Telemedicine Ltd at about CHF 39.7M (market capitalisation, as of Oct 2, 2026). Per share that is CHF 1.07; our models calculate a fair value of CHF 1.11 per share.
What do the bullish and bearish scenarios say about SHLTN?
Our models span a range for S H L Telemedicine Ltd: cautious scenario CHF 0.8840, base CHF 1.11, optimistic CHF 1.33 per share (as of Oct 2, 2026, price CHF 1.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of S H L Telemedicine Ltd (SHLTN)?
Balance-sheet figures for S H L Telemedicine Ltd (as of Oct 2, 2026): return on equity −36.9%, debt of 0.16 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is SHLTN from its 52-week high?
S H L Telemedicine Ltd trades at CHF 1.07, about 23% below its 52-week high of CHF 1.39 and 87% above the low of CHF 0.5720 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 1.11 is for.
Which stocks are comparable to S H L Telemedicine Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is S H L Telemedicine Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price CHF 1.07, calculated fair value CHF 1.11 (+3%), Quality Score 37/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SHLTN calculated?
We run S H L Telemedicine Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 1.11, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. S H L Telemedicine Ltd currently trades 3 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of S H L Telemedicine Ltd (SHLTN)?
The closing price on Oct 14, 2026 was CHF 1.07. Our model-based fair value is CHF 1.11, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with S H L Telemedicine Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of S H L Telemedicine Ltd

How large is the market capitalisation of S H L Telemedicine Ltd (SHLTN)?
The market capitalisation of S H L Telemedicine Ltd is CHF 39.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of S H L Telemedicine Ltd (SHLTN)?
The price-to-sales ratio of S H L Telemedicine Ltd is 0.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of S H L Telemedicine Ltd (SHLTN)?
Earnings per share at S H L Telemedicine Ltd are CHF −0.5100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of S H L Telemedicine Ltd (SHLTN)?
The net margin of S H L Telemedicine Ltd is −26.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of S H L Telemedicine Ltd (SHLTN)?
The return on equity (ROE) of S H L Telemedicine Ltd is −36.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of S H L Telemedicine Ltd (SHLTN)?
On an EBIT basis the return on assets of S H L Telemedicine Ltd is −10.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of S H L Telemedicine Ltd (SHLTN)?
The operating margin of S H L Telemedicine Ltd is −8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at S H L Telemedicine Ltd (SHLTN)?
Revenue at S H L Telemedicine Ltd is growing +12.2% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at S H L Telemedicine Ltd (SHLTN)?
Earnings per share at S H L Telemedicine Ltd are growing −90.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does S H L Telemedicine Ltd (SHLTN) generate?
The free cash flow of S H L Telemedicine Ltd is −$3.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does S H L Telemedicine Ltd (SHLTN) hold?
S H L Telemedicine Ltd holds more cash than debt, $12.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch S H L Telemedicine Ltd in the live analysis

One click puts S H L Telemedicine Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.